The Bahrain Cancer Society (BCS) is helping to advance the early detection of prostate cancer in the kingdom through the provision of cutting-edge diagnostic technology to the Salmaniya Medical Complex.
As part of the initiative, the society has announced payment of the first instalment for a high-resolution ultrasound device designed to improve early diagnosis of the disease.
Valued at BD115,000, the equipment will support the hospital’s urology department and is expected to be delivered in September this year.
BCS board chairman Dr Abdulrahman Fakhro said the initiative reflects the society’s ongoing commitment to strengthening early detection programmes.
“Supporting early detection programmes is among the key health priorities that the society is keen to continuously promote, given their direct impact on saving lives and improving patients’ quality of life,” he said.
“Acquiring the high-resolution ultrasound device represents a qualitative addition that will enhance the diagnostic capabilities of the urology department.”
The donation forms part of a broader series of healthcare initiatives led by the society, which contributed around BD200,000 between 2024 and 2025 towards the provision of specialised medical equipment supporting early cancer detection.
The society also continues to prioritise awareness and educational campaigns, emphasising that early diagnosis remains one of the most effective tools in improving treatment outcomes and reducing cancer incidence in Bahrain.
Prostate cancer remains one of the most common cancers among men in the kingdom. It is the fifth most prevalent cancer in Bahrain, affecting approximately 13.5 men per 100,000.
Regionally, Bahrain records one of the higher incidence rates in the Gulf.
Globally, prostate cancer is the second most common cancer in men, with nearly one in eight men diagnosed during their lifetime.
The disease involves the uncontrolled growth of cells in the prostate gland, part of the male reproductive system located below the bladder.
Because prostate cancer often develops without noticeable symptoms in its early stages, doctors stress the importance of regular screening.
Warning signs in later stages may include blood in the urine, persistent bone pain – particularly in the pelvis or lower back – a burning sensation during urination, and increased urinary frequency.
Health guidelines recommend annual blood tests measuring prostate-specific antigen (PSA), starting from age 40 for those with a family history of the disease, and from age 50 for others.
PSA is a protein produced by both normal and cancerous prostate cells and is used as an indicator in screening and monitoring.
julia@gdnmedia.bh
&uuid=(email))